2019
DOI: 10.33371/ijoc.v12i4.604
|View full text |Cite
|
Sign up to set email alerts
|

Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage 3B and 4 Breast Cancer Patients in Dharmais Hospital-National Cancer Center, Indonesia: A Cohort Study

Abstract: Background: There are no data of efficacy comparison between primary systemic therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared long term outcomes of breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) within a 6 cycles for NACT and 6 months for NA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
1
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 22 publications
0
1
0
1
Order By: Relevance
“…Pasien kanker payudara dengan stadium lanjut dan diketahui status hormonalnya kemudian diberikan neoajuvan hormonal terapi sebelum pembedahan menunjukkan overall survival yang lebih baik. 8 Pemeriksaan imunohistokima merupakan bagian dari faktor prognosis dan prediktif dan bermanfaat karena dapat merencanakan intervensi selain dari terapi bedah dan memprediksi hasil terapi serta prognosis. 9 Adanya pemeriksaan imunohistokimia di daerah diharapkan akan mempercepat diketahuinya diagnosis molekuler kanker payudara, sehingga terapi lebih sesuai.…”
Section: Pendahuluanunclassified
“…Pasien kanker payudara dengan stadium lanjut dan diketahui status hormonalnya kemudian diberikan neoajuvan hormonal terapi sebelum pembedahan menunjukkan overall survival yang lebih baik. 8 Pemeriksaan imunohistokima merupakan bagian dari faktor prognosis dan prediktif dan bermanfaat karena dapat merencanakan intervensi selain dari terapi bedah dan memprediksi hasil terapi serta prognosis. 9 Adanya pemeriksaan imunohistokimia di daerah diharapkan akan mempercepat diketahuinya diagnosis molekuler kanker payudara, sehingga terapi lebih sesuai.…”
Section: Pendahuluanunclassified
“…patients depends on technological advancement such as immunohistochemistry and biomolecular assay. 4,6 Management of breast cancer also has some adverse effects. In addition, factors of age, co-morbid disease , evidence-based study, cost effective utility, and when to stop the systemic treatment should be considered.…”
Section: Bioscientia Medicina: Journal Of Biomedicine and Translational Researchmentioning
confidence: 99%
“…It was reported by WHO that nearly 1.38 million cases of breast cancer were diagnosed in 2008 [1] , with a prevalence rate of 23% of all cancer cases in the world. In addition, it is known that 209,000 new cases were found, especially in Southeast Asia [2] . According to the International Agency on Research in Cancer, breast cancer has become the most common malignant tumor among Indonesian women [3] .…”
Section: Introductionmentioning
confidence: 99%
“…The results of the QSAR Machie learning quantitatively describe the pIC50 value of the compound and a qualitative description of the target protein. The pIC50 value is the same as Log IC50 Peronemine A2 (1) and B2 (2).…”
Section: Introductionmentioning
confidence: 99%